Cardiac function and hypertension in patients with obstructive sleep apnea

Adriana Bertolami
Carolina Gonzaga
Celso Amodeo
Sleep Laboratory of Dante Pazzanese Institute of Cardiology, São Paulo, Brazil

Abstract: Cardiovascular disease is one of the major causes of death worldwide. Among its risk factors, obstructive sleep apnea (OSA) is a common but still underestimated condition. OSA often coexists and interacts with obesity, sharing multiple pathophysiological mechanisms and subsequent cardiovascular risk factors, such as type 2 diabetes, dyslipidemia, systemic inflammation, and in particular hypertension. There is also evidence suggesting an increased risk of arrhythmia, heart failure, renal failure, acute myocardial infarction, stroke, and death. OSA is characterized by recurrent episodes of partial (hypopnea) or complete interruption (apnea) of breathing during sleep due to airway collapse in the pharyngeal region. The main mechanisms linking OSA to impaired cardiovascular function are secondary to hypoxemia and reoxygenation, arousals, and negative intrathoracic pressure. Consequently, the sympathetic nervous and the renin-angiotensin-aldosterone systems may be overstimulated, and blood pressure increased. Resistance to treatment for hypertension represents a growing issue, and given that OSA has been recognized as the major secondary cause of resistant hypertension, clinical investigation for apnea is mandatory in this population. Standard diagnosis includes polysomnography, and treatment for OSA should include control of risk factors for cardiovascular disease, including obesity. So far, continuous positive airway pressure is the treatment of choice for OSA, impacting positively on blood pressure goals; however, the impact on long-term follow-up and on cardiovascular disease should be better assessed.

Keywords: obstructive sleep apnea, hypertension, cardiac function

Introduction

Cardiovascular disease is a major cause of morbidity and mortality worldwide. The diagnosis and treatment of cardiovascular risk factors, such as hypertension, dyslipidemia, and type 2 diabetes, are therefore essential to reduce cardiovascular events. Among the risk factors for cardiovascular disease, obstructive sleep apnea (OSA) is a common but still underestimated condition, with over 85% of patients with clinically significant and treatable OSA having never been diagnosed. OSA often coexists and interacts with obesity, sharing multiple pathophysiological mechanisms and subsequent cardiovascular risk factors, such as type 2 diabetes, dyslipidemia, systemic inflammation, and in particular hypertension. There is also evidence suggesting an increased risk of arrhythmia, heart failure, renal failure, acute myocardial infarction, stroke, and death.

OSA affects around 5% of the general population, and the prevalence in patients referred to sleep laboratories is 50% using an apnea–hypopnea index (AHI) of ≥10 or 15 events per hour. Among hypertensive individuals, this prevalence
ranges from 30% to 40%, while 50% of patients with OSA are hypertensive.\textsuperscript{3,17–19} When resistant hypertension is considered, the prevalence of OSA increases up to 64%--83%, depending on the AHI considered for the diagnosis.\textsuperscript{20–23}

Diurnal hypersomnia due to frequent nocturnal arousals, asthenia, snoring, and witnessed apnea are the main symptoms of OSA. When OSA is suspected, the Epworth Sleepiness Scale or the Berlin Questionnaire could be used respectively to measure daytime sleepiness and to identify patients at higher risk for OSA.\textsuperscript{24,25}

Polysomnography is the standard method used to diagnose OSA and can be performed in a sleep laboratory or in the patient’s home. A complete polysomnography includes records of sleep, airflow (nasal pressure), respiratory effort (thoracic and abdominal respiratory movements), electroencephalography, and oxyhemoglobin saturation.

The aim of treatment for OSA is to achieve symptom control and to reduce cardiovascular risk, so a multidisciplinary approach is indicated. The treatment of choice is continuous positive airway pressure (CPAP), but other options include oral appliances\textsuperscript{26–29} and surgery, which, after decades, is still controversial, mainly because the criteria for surgical success are not well defined.\textsuperscript{30} Nowadays, its indication is restricted to selected cases, eg, for patients with refractory OSA or for those nontolerant to CPAP use.

Since CPAP adherence is a challenging issue, using a multidisciplinary approach is recommended, including physicians, nurses, physiotherapists, etc, to support the patient, in every step of CPAP use. It should include an explanation about the definition of OSA, the associated risk factors, prognosis, and benefit from treatment. The CPAP mask should be carefully chosen, and some patients may benefit from pressure relieve configuration, and humidifier device added to CPAP machine. Patients should be encouraged to mention complaints as soon as possible in order to resolve any issues that could impair adherence with CPAP.

### Normal sleep and the cardiovascular system

Some physiological changes that occur during normal sleep have been described. Nonrapid eye movement sleep accounts for about 80% of total sleep and is considered a cardiovascular relaxation state (Figure 1).\textsuperscript{31} During this period, heart rate, blood pressure, and sympathetic nervous system activity fall while vagal activity increases. There is also muscle relaxation, but basal tone is always maintained.\textsuperscript{31}

Rapid eye movement (REM) sleep comprises only 20%--25% of total sleep and is characterized by rapid eye movement (Figure 1). It is known for its paradoxical aspects, such as the presence of hypotonia and muscle atonia associated with phasic movements and multifocal myoclonus. The electrocardiogram and breathing show an irregular pattern, with alternating episodes of hypopnea and tachypnea, and central apneas. Sympathetic discharges and intermittent increases in heart rate and blood pressure occur in REM sleep; however, these events do not increase heart rate or mean arterial pressure above the usual values of wakefulness. REM sleep is also characterized by dreams and difficulty in awakening.\textsuperscript{31}

![Diagram of sleep phases](image_url)

**Figure 1** Physiological changes that occur during sleep phases.

**Abbreviations:** NREM, nonrapid eye movement; REM, rapid eye movement; HR, heart rate; BP, blood pressure.
Mechanisms of cardiac disturbance
OSA is characterized by recurrent episodes of partial (hypopnea) or complete (apnea) interruption of breathing during sleep due to airway collapse in the pharyngeal region. This collapse usually occurs on the posterior part of the tongue, uvula, and soft palate, or some combination of these structures.7

Hypoxemia and reoxygenation
Patients with OSA typically have repeated periods of desaturation and reoxygenation of oxyhemoglobin (Figure 2). This may partly explain the increase in blood pressure due to chemoreflex-mediated increases in sympathetic activity that induces peripheral vasoconstriction.7,32,33 Another pathway for maintaining high blood pressure is related to activation of the renin–angiotensin–aldosterone system, which is also triggered by intermittent hypoxemia.34 Further, there is increased oxidative stress and reduced production of endothelium-dependent vasodilator substances,35,36 such as nitric oxide,37 contributing to activation of systemic inflammation.

Hypoxemia has direct and indirect cardiac and vascular effects, including decreased oxygen delivery to the myocardium, and activation of the sympathetic nervous system, promotion of endothelial cell dysfunction, and pulmonary arteriolar vasoconstriction.38 Hypoxemia with reoxygenation may be analogous to ischemia with reperfusion, and may cause additional damage through further production of free radical species.38

Decreased myocardial oxygen delivery may result in an imbalance between oxygen consumption and demand, causing myocardial hypoxia, mainly in patients with coronary artery disease.38 Endothelial cells in the coronary vessels also play a central role in vasoregulation, coagulation, and inflammation.39 Blood flow and coagulation are modulated by production and release of vasoactive substances, a balance of which is important in modulating coronary artery blood flow and coagulation.38

The pathophysiological consequences of hypoxemia and reoxygenation could lead to vascular inflammation and remodeling, similar to atherosclerosis.38–40 OSA increases sympathetic activity via complex mechanisms. Hypoxemia stimulates peripheral arterial chemoreceptors in the carotid bodies, triggering increased reflex sympathetic activity.38,41,42 Hypercapnia acts primarily on central chemoreceptors located in the region of the brainstem, also increasing sympathetic activity.38

Arousals
Sleep architecture is altered in patients with OSA, who show a prevalence of light sleep stages, resulting in arousals that are associated with an increase in sympathetic activity, a decrease in parasympathetic activity, and elevation of blood pressure and heart rate.7,38,43,44

**Figure 2** Pathophysiological consequences of obstructive sleep apnea.

*Note:* Reprinted from *Principles and Practice of Sleep Medicine*. 5th ed; Kryger MH, Roth T, Dement WC, editors. Somers VK, Javaheri S. Cardiovascular effects of sleep-related breathing disorders, 1370–1380. © 2011, with permission from Elsevier.38

**Abbreviations:** H/R, hypoxia-reoxygenation; L, left; R, right; RV, right ventricular; SVR, systemic vascular resistance; ↓, decrease; ↑, increase; Ppl, pleural pressure; O2, oxygen; H2O, water; P, pressure; PCO2, partial pressure of carbon dioxide.
Negative intrathoracic pressure
During the obstructive episode, generation of a significant gradient of negative pressure in the thoracic cavity is required in order to open the upper airway. This increases the transmural pressure of the intrathoracic vascular structures, including the aorta, pulmonary vascular bed, and ventricles, possibly resulting in cardiovascular hemodynamic and structural changes.

Hypertension
Hypertension is currently the most important risk factor for cardiovascular disease, which is a leading cause of death worldwide. In spite of efforts to reach blood pressure targets, the results have been disappointing in most countries. Canada shows a control rate of 65%, while in the USA it is only 50%, and less than one third in other parts of the world. Since the prevalence of difficult to control hypertension has increased in recent decades, patients with so-called resistant hypertension have become a remarkable clinical entity.

Resistant hypertension is defined by patients being treated, for at least three months, with three classes of antihypertensive drugs at optimal doses, ideally one being a diuretic, without blood pressure control, or requiring or more classes to achieve the therapeutic goal.

Although the exact prevalence is still discussed, it is estimated that 20%–30% of patients in clinical trials have resistant hypertension. More recently, however, studies analyzing the prevalence of resistant hypertension showed lower percentages between 12% and 16%. Aging and obesity are important risk factors leading to decreased blood pressure control, and the incidence of resistant hypertension tends to increase as the population becomes older and more obese.

Among hypertensive patients, at least 5%–10% have an identifiable etiology for their hypertension, characterizing a secondary cause of the increased blood pressure. Excluding poor adherence with proposed therapy and the effect of white coat hypertension, secondary causes for hypertension must be screened for, such as OSA, aldosteronism, kidney disease, pheochromocytoma, and renovascular disease, especially in patients with resistant hypertension. Given that OSA has been recognized as the major secondary cause of resistant hypertension, clinical investigation for apnea is mandatory in this population.

Blood pressure pattern and OSA
Classically, OSA has been associated with a “nondipping blood pressure profile”, usually defined as a nocturnal fall in blood pressure of less than 10%, regardless of the presence of hypertension in the daytime. However, more recent data disagree with this paradigm. Although controversial, there are studies suggesting that the time between ambulatory blood pressure monitoring measurements should be less in patients with OSA. On the other hand, age-related differences have been described, suggesting that severe apnea may cause nondipping blood pressure only in young OSA patients, whereas, in the elderly, impaired sleep quality was more prevalent.

In general, the nondipping blood pressure pattern during sleep results from increased sympathetic activity during this period, due to four main stimuli, ie, intermittent hypoxemia, hypercapnia, lack of proper inflation of the lungs, and awakenings at the end of episodes of apnea. The cumulative effect of excessive sympathetic activation together with other vasoactive factors released in response to hypoxia can result in sustained daytime hypertension in these patients.

Aldosterone and fluid retention
The high prevalence of OSA in people with resistant hypertension suggests that particular pathophysiological mechanisms may be involved. In patients with resistant hypertension, high sodium intake leads to increased fluid retention, which could make edema in the region of the upper airways worse. Consistent with this hypothesis, it has been observed that individuals with resistant hypertension have more intense volume redistribution during sleep when compared with individuals who do not have resistant hypertension, and due to the horizontal position, the excess amount withheld during wakefulness is directed from the lower limbs to the cervical region.

Parallel to resistant hypertension, it is questionable whether OSA itself could lead to increased volume retention. Activation of the renin–angiotensin–aldosterone system and sympathetic nervous system alone explains this phenomenon, in addition to the hypertension resulting from activation of these systems.

Other studies indicate that measures reducing fluid retention may contribute to improved AHI in patients with OSA, including use of compression stockings in those with chronic venous insufficiency, regular physical activity, and spironolactone.

Among subjects with resistant hypertension, a significant prevalence of aldosteronism can be observed, that reaches 28%. In individuals with resistant hypertension, aldosterone excess promotes greater fluid retention, worsening OSA severity. On the other hand, OSA may further increase sympathetic nervous and renin–angiotensin–
aldosterone systems activity, exacerbating volume retention, and deteriorating blood pressure. In order to assess this pathway better, patients with resistant hypertension and OSA were investigated by Gaddam et al before and 8 weeks after having spironolactone 25–50 mg/day added to their ongoing antihypertensive therapy.60 After treatment, the AHI was significantly reduced from 39.8±19.5 events per hour to 22.0±6.8 events per hour (P<0.05).60 Although it is not possible to directly infer causality from these studies, the results are consistent with the hypothesis that an excess of aldosterone may contribute to worsening severity of OSA, perhaps secondary to increased airway edema.61

Elevated levels of aldosterone and angiotensin II have been observed in OSA, and, interestingly, these levels have been shown to decrease after treatment with CPAP.69

Currently, the role of OSA as a risk factor for hypertension is well established.13,70–77 Individuals diagnosed with hypertension are about twice as likely to have OSA than individuals without hypertension.71 The odds ratios for the presence of hypertension at 4-year follow-up are 1.4 (95% confidence interval 1.1–1.8) for patients with an AHI of 0.1–4.9 events per hour, 2.0 (95% confidence interval 1.3–3.2) with an AHI of 5.0–14.9 events per hour, and 2.9 (95% confidence interval 1.5–5.6) with an AHI ≥15.0 events per hour72 at baseline as compared with those without respiratory events. In conclusion, hypertension presence is correlated to OSA severity.

Renal denervation
Renal sympathetic denervation has been evaluated in several studies as a therapeutic option for patients with resistant hypertension, because it reduces systemic sympathetic activity. At 6-month follow-up, the Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2) trial (ClinicalTrials.gov identifier NCT00888433) showed that patients undergoing denervation had a greater reduction in blood pressure from baseline compared with a control group that was not subjected to the procedure.73 Interestingly, a review of ten patients with resistant hypertension undergoing renal sympathetic denervation showed a trend towards reduction in AHI from baseline (mean 16.3 events versus 4.5 events per hour, P=0.059).74 This finding was attributed to, among other factors, lower renal and systemic sympathetic activation that could have been achieved with renal denervation, further leading to lower activation of the renin–angiotensin–aldosterone system and therefore lower volume retention. It is important to note that data from the recent published SYMPPLICITY HTN-3 trial, a single-blind, randomized controlled trial, failed to show blood pressure decrease after renal denervation in subjects with resistant hypertension.75

Arrhythmias
Cardiac arrhythmias are common in patients with OSA, and the prognosis is highly dependent on the presence of underlying heart disease.76 Cardiac arrhythmias such as atrial fibrillation77,78 and ventricular arrhythmia78,79 are common in patients with OSA, and are associated with increased risk of sudden death during sleep.80 Over 50% of patients with OSA have nocturnal arrhythmias and the frequency of arrhythmias increases with the AHI and severity of hypoxemia.81 The risk of an episode of atrial fibrillation or nonsustained ventricular tachycardia 90 minutes after an episode of apnea/hypopnea is 18 times higher than during periods of normal breathing.81

In 2006, Mehra et al78 compared 228 patients with and 338 patients without respiratory sleep disorders. Patients with severe disturbances showed a 2–4-fold increased risk of nocturnal complex arrhythmias such as atrial fibrillation and nonsustained ventricular tachycardia, even after adjustment for age, sex, body mass index, and presence of coronary artery disease. In 2009, Monahan et al81 studied 57 patients with sleep-disordered breathing in order to establish a direct temporal relationship between the presence of the disorder and the formation of arrhythmias. In these patients, there was an increased relative risk of paroxysmal atrial fibrillation and nonsustained ventricular tachycardia during sleep shortly after an episode of apnea/hypopnea.

Atherosclerosis
Atherosclerosis is the pathophysiological basis for most cardiovascular diseases, and its relationship with OSA has been demonstrated in several studies.82 Among the main mechanisms involved are intermittent hypoxia associated with increased oxidative stress, endothelial dysfunction, and inflammatory activity.75,82–84 Consequently, dyslipidemia, hypertension, and other cardiovascular risk factors may occur,75,83,85 the final outcome of which is often death by acute coronary syndrome or stroke.86

A prospective study of 4,422 patients with a mean follow-up of 8.7 years, after adjustment for multiple risk factors and excluding patients with coronary artery disease and heart failure, showed that OSA was a significant risk factor for myocardial infarction, need for coronary revascularization, and death from coronary artery disease only in men younger
Left ventricular hypertrophy may be associated with OSA independently of blood pressure, mainly because of post-load elevation during apnea events and sympathetic activation. The prevalence of left ventricular hypertrophy increases as the severity of OSA increases.

OSA also contributes to the progression of heart failure via other mechanisms, such as increased sympathetic stimulation of the heart, kidneys, and blood vessels during sleep and wakefulness, hypercapnia, daytime blood pressure, and loss of vagal regulation of heart rate. These mechanisms are recurrent during sleep and cause significant pressure overload in the left ventricle, as well as necrosis and apoptosis of myocytes, and are responsible for the increased risk of acute myocardial infarction, systolic dysfunction, arrhythmias, and cardiac remodeling.

Impact of OSA treatment on blood pressure

Since a 10% decrease in body weight can reduce the AHI and improve oxygenation, sleep architecture, blood pressure, and self-reported alertness, control of obesity should be aimed for. The benefit of effective treatment of OSA with CPAP for blood pressure is proportional to its length of use and is demonstrated by a reduction in sympathetic activity. Meta-analyses suggest that regular CPAP therapy for at least 5 hours per night in patients with OSA results in benefit, reducing both systolic and diastolic blood pressure, with a decrease of 1.69 mmHg in mean blood pressure levels measured during 24-hour ambulatory monitoring. The best predictors of response are the severity of OSA, higher blood pressure levels, and greater adherence to CPAP.

However, not all studies confirm these benefits, and their results should be interpreted with caution, considering the different study designs, inclusion of heterogeneous populations, variations in the definition of hypertension and OSA, classification of OSA severity, duration of use of CPAP, and the methods used to monitor blood pressure. On the other hand, there is no current evidence that any specific antihypertensive drug has a direct effect on attenuating the severity of OSA, but there is some evidence that some of these agents can interfere with sleep architecture.

Conclusion

The relationship between sleep-disordered breathing, cardiovascular disease, and its risk factors have been described, but prospective studies analyzing their relationship and the long-term prognosis are still needed. Nevertheless, alterations in
cardiac function along with hypertension are well established complications of OSA, demanding particular attention to OSA diagnosis in hypertensive patients. Despite the reported benefits of CPAP in the treatment of OSA, the CPAP impact on long-term follow-up and on cardiovascular disease should be better assessed.

### Disclosure

The authors report no conflicts of interest in this work.

### References


